Magenta Therapeutics Inc (OQ:MGTA)

Sep 11, 2020 08:00 am ET
Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in September
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company will participate in the following September investor conferences:
Sep 02, 2020 12:00 pm ET
Magenta Therapeutics Named Co-Recipient of Grant from the National Institutes of Health to Explore Use of Novel Targeted Conditioning Agents with Gene Editing Approaches to Cure HIV
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced it is part of a multi-project, broad-based research effort awarded a five-year, $14.6 million U19 grant from the National Institutes of Health (NIH) to explor
Sep 02, 2020 08:00 am ET
Magenta Therapeutics Appoints Lisa M. Olson as Chief Scientific Officer and Kevin B. Johnson as Senior Vice President, Head of Regulatory and Quality; Announces Transition of Jason Ryan, Chief Operati
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced the appointment of two new executives, Lisa M. Olson, Ph.D., as Chief Scientific Officer and Kevin B. Johnson, Ph.D., as Senior Vice President, Head of Regula
Aug 31, 2020 08:00 am ET
Magenta Therapeutics Announced It Will Present Clinical and Pre-Clinical Data from Across Immune and Blood System Reset Portfolio at European Society for Blood and Marrow Transplantation (EBMT) Annual
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that data across the portfolio will be presented at the European Society for Blood and Marrow Transplantation (EBMT) annual meeting, held August 29 to
Aug 06, 2020 08:00 am ET
Magenta Therapeutics Reports Recent Business Highlights and Second Quarter Financial Results
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today reported recent business highlights and financial results for the second quarter ended June 30, 2020.
Aug 03, 2020 04:05 pm ET
Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in August
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company will participate in the following August investor conferences:
Jul 15, 2020 07:58 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Magenta Therapeutics, Inc. - MGTA
Pomerantz LLP is investigating claims on behalf of investors of Magenta Therapeutics, Inc. (“Magenta” or the “Company”) (NASDAQ: MGTA). Such investors are advised to contact Robert S. Willoughby at or 888-476-6529, ext. 7980. The investigation...
Jun 30, 2020 08:00 am ET
Magenta Therapeutics Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced the closing of its previously announced underwritten public offering of 8,625,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,125,000 shares, at a price to the public of $8.00 per share. The total gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected
Jun 24, 2020 08:20 pm ET
Magenta Therapeutics Announces Pricing of Public Offering
Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced the pricing of an underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $8.00 per share. Magenta also granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $60.0 m
Jun 24, 2020 05:46 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA
NEW YORK, June 24, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ: MGTA).  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980....
Jun 24, 2020 05:46 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA
NEW YORK, June 24, 2020 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors of  Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ: MGTA).  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980....
Jun 24, 2020 04:21 pm ET
Magenta Therapeutics Launches Proposed Public Offering
Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced that it has commenced an underwritten public offering of $60 million of its common stock. Magenta also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares in the proposed offering are to be sold by Magenta.
Jun 22, 2020 06:54 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA
Pomerantz LLP is investigating claims on behalf of investors of Magenta Therapeutics, Inc. (“Magenta” or the “Company”) (NASDAQ: MGTA). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....
Jun 16, 2020 03:03 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA
Pomerantz LLP is investigating claims on behalf of investors of  Magenta Therapeutics, Inc. (“Magenta” or the “Company”) (NASDAQ: MGTA).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....
Jun 15, 2020 11:00 am ET
MGTA Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Magenta Therapeutics, Inc. and Encourages Investors to Contact the Firm
NEW YORK, June 15, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ: MGTA). Investors who purchased Magenta securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/mgta.                        ...
Jun 15, 2020 06:00 am ET
Jun 11, 2020 03:09 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA
Pomerantz LLP is investigating claims on behalf of investors of  Magenta Therapeutics, Inc. (“Magenta” or the “Company”) (NASDAQ: MGTA).  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....
Jun 11, 2020 07:30 am ET
Magenta Therapeutics Provides Portfolio Update: Stem Cell Mobilization and Conditioning Programs Prioritized and Advancing Toward Clinical Milestones
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today provided a portfolio update, highlighting progress and recent updates across its most advanced programs.
Jun 08, 2020 04:30 pm ET
Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company will participate in a fireside chat and hold investor meetings at the 41st annual Goldman Sachs Healthcare Conference on June 11
Jun 05, 2020 08:30 am ET
Magenta Therapeutics Presents Data Supporting Immune Reset for Autoimmune Diseases
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today reported the presentation of preclinical data showing successful immune reset with a single dose of its CD45-ADC in models of three autoimmune diseases. Magenta also highlighted data from its Phase 1 study of first-line stem cell mobilization therapy MGTA-145. These results were presented this week at the European League Against Rheumatism (EULAR) annual meeting.
May 14, 2020 08:00 am ET
Magenta Therapeutics Presents Data at Annual Meeting of American Society of Gene and Cell Therapy Demonstrating Cells Mobilized with MGTA-145 in a Phase I Trial Are Effective in Gene Therapy Settings
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of blood and immune reset to more patients, presented preclinical data on its stem cell mobilization therapy clinical candidate, MGTA-145, this week at the annual meeting of the American Society of Gene and C
May 07, 2020 07:30 am ET
Magenta Therapeutics Reports Recent Business Highlights and First Quarter Financial Results
“The first quarter of 2020 has shown Magenta to be well-positioned to advance our programs and to weather unexpected obstacles. Magenta continues to execute and progress our pipeline, and we remain committed wholeheartedly to our patients, their families, our employees and our business partners,” said Jason Gardner, D.Phil., President and Chief Executive Officer, Magenta. “In this first quarter, Magenta has showcased significant clinical and preclinical results, and we are building on these results to advance quickly.”
May 06, 2020 07:00 am ET
May 06, 2020 07:00 am ET
Apr 30, 2020 08:00 am ET
Magenta Therapeutics to Host Business Update Conference Call
Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced it will host a conference call on Thursday, May 7, 2020 at 8:00am ET to discuss recent business updates. The call will also feature a discussion of current ste
Apr 28, 2020 04:30 pm ET
Magenta Therapeutics to Present Data from Across Portfolio at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that data from across its portfolio will be presented at the ASGCT annual meeting, to be held May 12-15, 2020.
Apr 17, 2020 08:11 am ET
Magenta Therapeutics Names John Davis Jr., M.D., M.P.H, M.S., Head of Research and Development
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that it has promoted John Davis Jr., M.D., M.P.H., M.S. to Head of Research and Development and Chief Medical Officer.
Apr 16, 2020 08:00 am ET
Magenta Therapeutics Provides Business Update
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today provided a current update on its programs, business and operations.
Mar 03, 2020 08:00 am ET
Magenta Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today reported financial results for the fourth quarter and full year ended December 31, 2019 and recent business highlights.
Feb 26, 2020 08:30 am ET
Magenta Therapeutics to Participate in Cowen Health Care Conference on Monday, March 2nd in Boston
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company is scheduled to participate in a fireside chat at the 40th annual Cowen Health Care Conference on Monday, March 2nd, 2020, at 4:10
Feb 24, 2020 08:30 am ET
Magenta Conditioning Lead Clinical Candidate MGTA-117 Demonstrates Broad Tolerability and High Therapeutic Index in Non-human Primates
Magenta has created a new stem cell biology discovery platform to harness the curative power of immune reset through stem cell transplant for more patients, and is developing a comprehensive portfolio of novel therapeutics to allow more patients to benefit through a more precise stem cell transplant process. This portfolio includes targeted, disease-modifying antibody drug conjugates (ADCs), such as MGTA-117, that are designed to precisely and rapidly remove the disease-causing cells in the body and enable immune system reset and long-term engraftment without the need for chemotherapy or radia
Feb 24, 2020 08:30 am ET
Magenta Therapeutics Completes Dosing in Phase 1 MGTA-145 Trial, Demonstrating Rapid, Single-Day First Line Stem Cell Mobilization and Collection
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced the completion of dosing in its Phase 1 trial of stem cell mobilization therapy clinical candidate, MGTA-145, as well as updated clinical data from the trial
Feb 20, 2020 08:30 am ET
Magenta Therapeutics Announces Updated Phase 2 Data on MGTA-456 Cell Therapy, Demonstrating Continued Durability in Inherited Metabolic Disorders
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced updated clinical data from Phase 2 trials of its cell therapy, MGTA-456, at the Transplant and Cellular Therapy (TCT) Annual Meeting in Orlando, Florida. New
Feb 06, 2020 08:30 am ET
Magenta Therapeutics to Participate in Guggenheim Healthcare Talks Oncology Day on Thursday, February 13th in New York City
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company is scheduled to participate in a fireside chat at the Guggenheim Healthcare Talks Oncology Day on Thursday, February 13th, 2020, a
Feb 05, 2020 08:30 am ET
Magenta Therapeutics Expands Leadership Team, Appoints Kristen Stants as Chief People Officer and Li Malmberg as Senior Vice President, Head of Manufacturing
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced the expansion of its senior leadership with two new strategic hires, Kristen Stants as Chief People Officer and Li Malmberg, Ph.D., as Senior Vice President,
Jan 13, 2020 08:00 am ET
Magenta Therapeutics Advances Conditioning Platform and Clinical Programs, Highlights Recent Milestones and 2020 Goals
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today highlighted recent progress across several programs and outlined goals for 2020. These updates will be discussed during a webcast presentation at the 38th an
Jan 06, 2020 08:30 am ET
Magenta Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th in San Francisco
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company is scheduled to present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 15th
Dec 09, 2019 07:45 am ET
Magenta Therapeutics Demonstrates First-ever Successful Gene Therapy Transplant Without Chemotherapy in Primates Using a Single Dose of Antibody-drug Conjugate
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that new results from its CD117-ADC patient preparation program were presented at the 61st Annual Meeting of the American Society of Hematology (AS
Dec 07, 2019 05:30 pm ET
First Clinical Data with MGTA-145 Show Single-Day Dosing and Collection of Robust Numbers of High-Quality Stem Cells in Healthy Volunteers
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that new results from its MGTA-145 stem cell mobilization program were presented at the 61st Annual Meeting of the American Society of Hematology (
Nov 26, 2019 04:05 pm ET
Magenta Therapeutics to Present at the Evercore ISI HealthCONx Conference on Tuesday, December 3rd
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that the Company is scheduled to participate in a fireside chat at the Evercore ISI HealthCONx Conference on December 3, 2019 at 1:15 p.m. ET at the F
Nov 13, 2019 08:00 am ET
Magenta Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today reported financial results for the third quarter ended September 30, 2019 and recent business highlights.
Nov 11, 2019 08:30 am ET
Magenta Therapeutics Presents First Immune Reset Results with Antibody-Drug Conjugate Across Multiple Autoimmune Diseases at ACR
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today reported new data showing successful immune reset with a single dose of its CD45-ADC in models of three autoimmune diseases. These results were presented yesterday at the American College of Rheumatology (ACR) Annual Meeting in Atlanta, Ga.
Nov 06, 2019 09:00 am ET
Magenta Therapeutics to Present New Clinical and Preclinical Data at American Society of Hematology (ASH) Annual Meeting
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that new data from across its pipeline will be presented at the 61st Annual Meeting of the American Society of Hematology (ASH).
Oct 16, 2019 08:30 am ET
Magenta Therapeutics Appoints Jan Pinkas as Senior Vice President, Head of Translational Sciences and Announces Transition of Chief Scientific Officer
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced the appointment of Jan Pinkas, Ph.D., as Senior Vice President, Translational Sciences. The Company also announced that Mike Cooke, Ph.D., Chief Scientific Officer,
Sep 04, 2019 08:30 am ET
Magenta Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to MGTA-456 for the Treatment of Inherited Metabolic Disorders
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advance Therapy (RMAT) designation for MGTA-456, a one-time cell therapy for the treat
Aug 08, 2019 08:00 am ET
Magenta Therapeutics Reports Second Quarter 2019 Financial Results and Recent Business Highlights
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today reported financial results for the second quarter ended June 30, 2019 and recent business highlights.
Aug 06, 2019 08:30 am ET
Magenta Therapeutics to Present at the Wedbush PacGrow Healthcare Conference on Tuesday, August 13th
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that the Company is scheduled to present at the Wedbush PacGrow Healthcare Conference on August 13, 2019 at 3:05 p.m. ET at the Parker New York in New York City.
Jul 12, 2019 02:29 pm ET
CORRECTING and REPLACING Magenta Therapeutics Appoints Anne McGeorge to Board of Directors
Reissuing release dated June 24th, 2019 to correct for searching purposes.
Jun 06, 2019 04:05 pm ET
Magenta Therapeutics to Present at the 40th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11th
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that the Company is scheduled to present at the Goldman Sachs Global Healthcare Conference on June 11, 2019 at 2:40 p.m. PT/5:40
May 09, 2019 08:00 am ET
Magenta Therapeutics Reports First Quarter 2019 Financial Results and Recent Business Highlights
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today reported financial results for the first quarter ended March 31, 2019 and recent business highlights.
May 09, 2019 07:30 am ET
Magenta Therapeutics Presents Updated Phase 2 Clinical Data on MGTA-456 Cell Therapy at American Academy of Neurology Annual Meeting
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that the Company presented Phase 2 clinical data on its cell therapy, MGTA-456, at the annual meeting of the American Academy of Neurol
May 06, 2019 04:05 pm ET
Magenta Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced the closing of its previously announced public offering of 4,887,500 shares of its common stock, including 637,500 shares
May 01, 2019 08:11 pm ET
Magenta Therapeutics Announces Pricing of Public Offering
Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced the pricing of its public offering of 4,250,000 shares of its common stock at a price to the public of $13.25 per share,
Apr 29, 2019 04:32 pm ET
Magenta Therapeutics Launches Proposed Public Offering
Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that it has launched a proposed public offering of 4,250,000 shares of its common stock.
Apr 29, 2019 08:00 am ET
Magenta Therapeutics to Present Preclinical Data on E478 Stem Cell Gene Therapy Expansion Program at the 2019 Annual Meeting of the American Society of Gene and Cell Therapy
Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced the Company will highlight preclinical data on its E478 program in an oral presentation on Thursday, May 2, at the annual meeting of the
Apr 24, 2019 08:30 am ET
Magenta Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of MGTA-145, a First-Line Stem Cell Mobilization Product Candidate
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that it has dosed the first subjects in a Phase 1 study of MGTA-145. Magenta intends to develop MGTA-145 in autoimmune diseases, blood
Mar 19, 2019 07:30 am ET
Magenta Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2018.
Mar 06, 2019 04:05 pm ET
Magenta Therapeutics to Present at Investor Conferences in March
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that the Company is scheduled to present at the following investor conferences:
Feb 25, 2019 08:15 am ET
Magenta Therapeutics Presents Clinical and Preclinical Data on MGTA-456 Cell Therapy in Best Abstracts Sessions at Transplant and Cellular Therapy (TCT) Annual Meeting
Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that the Company presented Phase 2 clinical data and preclinical research on its MGTA-456 program at the TCT annual meeting.
Feb 25, 2019 08:15 am ET
Magenta Therapeutics Presents Preclinical Data on Targeted Non-Genotoxic Conditioning Programs, Including First Conditioning Development Candidate
Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that the Company highlighted preclinical research on its targeted conditioning programs in four presentations and posters at the Transpl
Feb 21, 2019 08:00 am ET
Magenta Therapeutics Presents Preclinical Data on MGTA-145, First-Line Stem Cell Mobilization Product Candidate for Autologous and Allogeneic Bone Marrow Transplant
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that the Company presented new preclinical research on its MGTA-145 product candidate for stem cell mobilization at the Transplant an
Feb 07, 2019 08:30 am ET
Magenta Therapeutics to Present at Guggenheim Healthcare Investor Conference
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that the Company is scheduled to present at the Guggenheim Healthcare Talks Idea Forum Oncology Day on Thursday, February 14th
Jan 02, 2019 08:30 am ET
Magenta Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that the company is scheduled to present and subsequently participate in a Q&A session at the 37th Annual J.P. Morgan Heal
Dec 02, 2018 09:00 pm ET
Magenta Therapeutics Presents New Data from Phase 2 Study of MGTA-456 Cell Therapy in Patients with Inherited Metabolic Disorders
Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that the Company presented initial Phase 2 clinical data and preclinical research on its MGTA-456 program at the 60th annual meeting o
Dec 02, 2018 09:00 pm ET
Magenta Therapeutics Presents Preclinical Data on Targeted Non-Genotoxic Conditioning Programs Demonstrating Potent Stem Cell Depletion and Anti-Leukemia Survival Benefit
Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that the Company presented preclinical research on its targeted conditioning programs at the 60th annual meeting of the American Socie
Dec 01, 2018 12:30 pm ET
Magenta Therapeutics Presents New Preclinical Data on MGTA-145 Stem Cell Mobilization Product Candidate
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that the Company highlighted new preclinical research on its MGTA-145 product candidate for stem cell mobilization in an oral present
Nov 26, 2018 08:30 am ET
Magenta Therapeutics to Host Webcast of Investor and Analyst Event During ASH
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that it will host a live webcast of an investor and analyst event at 8:30 p.m. PST (11:30 p.m. EST) on Sunday, December 2, 2018, durin
Nov 19, 2018 08:00 am ET
Magenta Therapeutics Appoints Jason Ryan as Chief Operating and Financial Officer
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that it has strengthened its executive team with the appointment of Jason Ryan as Chief Operating and Financial Officer, effective Ja
Nov 08, 2018 08:00 am ET
Magenta Therapeutics Reports Recent Operational Progress and Third Quarter 2018 Financial Results
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today reported financial results and business highlights for the third quarter ended September 30, 2018.
Nov 01, 2018 09:00 am ET
Magenta Therapeutics Announces Acceptance of Nine Abstracts Covering Clinical and Preclinical Data at ASH, Representing Progress across the Portfolio of Conditioning, Stem Cell Mobilization and Expans
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that the Company will present clinical data and preclinical research at the 60th annual meeting of the American Society of Hematology
Sep 24, 2018 08:30 am ET
Magenta Therapeutics Added to Russell 2000 and 3000 Indexes
Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that the company has been added to the Russell 2000 and 3000 indexes following the Russell U.S. Indexes’ quarterly update.
Aug 09, 2018 04:05 pm ET
Magenta Therapeutics Reports Recent Operational Progress and Second Quarter 2018 Financial Results
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today reported financial results and business highlights for the second quarter ended June 30, 2018.
Aug 08, 2018 04:05 pm ET
Magenta Therapeutics to Present at Wedbush PacGrow Healthcare Conference
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that the Company is scheduled to present at the 2018 Wedbush PacGrow Healthcare Conference on Tuesday, August 14th, at 9:10
Jun 25, 2018 04:05 pm ET
Magenta Therapeutics Announces Closing of Initial Public Offering
Magenta Therapeutics, Inc. (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced the closing of its initial public offering of 6,666,667 shares of its common stock at a price to the public of $15.00 per share.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.